Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 12:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–15 of 15 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Fycompa Clear all

Conditions: Intractable Epilepsy, Malignant Glioma, Seizure Disorder, WHO Grade 2 Glioma, WHO Grade 3 Glioma
Interventions: Anticonvulsant Agent, Perampanel, Quality-of-Life Assessment, Questionnaire Administration; Drug · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Refractory Status Epilepticus
Interventions: Perampanel; Drug
Lead sponsor: Wayne State University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Catamenial Epilepsy
Interventions: Fycompa, Fycompa with a boost; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Pediatric Epileptic Syndrome, Partial-onset Seizures
Interventions: Perampanel Oral Suspension, Perampanel Tablet; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 1 Month to 18 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 15
States / cities: Los Angeles, California • Aurora, Colorado • Miami, Florida + 12 more

Conditions: Partial Onset Seizures, Secondarily Generalized Seizures, Primary Generalized Tonic-Clonic Seizures
Interventions: Perampanel; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 4 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 24
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 20 more

Conditions: Heart Arrest, Seizures, Status Epilepticus
Interventions: Perampanel, Placebo; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Epilepsy
Interventions: Fycompa; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: Not listed
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 44
States / cities: Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 31 more

Conditions: Epilepsy
Interventions: perampanel; Drug
Lead sponsor: Mid-Atlantic Epilepsy and Sleep Center, LLC; Other
Eligibility: 18 Years to 65 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Epilepsy
Interventions: Perampanel 1 week titration, Perampanel 2 week titration, Perampanel 4mg, Placebo; Drug
Lead sponsor: Kimford Jay Meador; Other
Eligibility: 18 Years to 55 Years
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 3
States / cities: Palo Alto, California • Chicago, Illinois • New York, New York

Conditions: Glioma, Malignant, Surgery, Seizures
Interventions: Perampanel, Standard of Care; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Perampanel, Placebo Oral Tablet; Drug
Lead sponsor: Stony Brook University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Stony Brook, New York

Conditions: Brain Tumor, Primary
Interventions: Perampanel; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Neuropathy, Small Fiber
Interventions: Fycompa, Placebo; Drug
Lead sponsor: PNA Center for Neurological Research; Other
Eligibility: 18 Years to 60 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Perampanel, Placebo; Drug · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 70 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Epilepsy
Interventions: Perampanel Oral Tablet; Drug
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Phoenix, Arizona

Search by objective public record fields.

Perampanel for the Reduction of Seizure Frequency in Patients With High-grade Glioma and Focal Epilepsy

Efficacy and Safety of Perampanel in the Treatment of Refractory Status Epilepticus

Fycompa in Catamenial Epilepsy

A Study to Evaluate Efficacy and Safety of Perampanel Administered as an Adjunctive Therapy in Pediatric Participants With Childhood Epilepsy

Study to Evaluate the Efficacy and Safety of Perampanel as Monotherapy or First Adjunctive Therapy in Subjects With Partial Onset Seizures With or Without Secondarily Generalized Seizures or With Primary Generalized Tonic-Clonic Seizures

PeRampanel fOr Status ePilEpticus pRophylaxis Post-cardiac Arrest

Study to Investigate Dosage, Efficacy, and Safety of Fycompa in Routine Clinical Care of Patients With Epilepsy

Perampanel for Treatment of Adults With Refractory Focal Epilepsy : a Pilot Study.

Perampanel Titration and Cognitive Effects

Effect of Perampanel on Peritumoral Hyperexcitability in HGG

A Clinical Trial to Evaluate the Safety and Efficacy of Fycompa in Subjects With Amyotrophic Lateral Sclerosis (ALS)

Perampanel in Seizure Patients With Primary Glial Brain Tumors

Fycompa in Subjects With Small Fiber Neuropathy (SFN)

Perampanel Single Ascending Dose Transcranial Magnetic Stimulation Biomarker Study in Amyotrophic Lateral Sclerosis

Fycompa Titration Intervals and Effects on Retention Rate